Citius shares surge 10.63% premarket after positive Phase I trial results for LYMPHIR combination therapy.

Citius Pharmaceuticals (CTXR) surged 10.63% in premarket trading following multiple positive developments. The stock gained momentum after D. Boral Capital reaffirmed its 'Buy' rating with a $6.00 price target, maintaining confidence in the company’s valuation. Additionally, Citius Oncology, a subsidiary, reported positive topline results from an investigator-initiated Phase I clinical trial evaluating LYMPHIR in combination with other therapies, signaling potential progress in oncology drug development. The repeated 'Buy' ratings and the clinical trial milestone collectively reinforced investor optimism, driving the premarket rally.